Purpose-built for physicians Tirzepatide tied to lower cardiovascular risk than dulaglutide in type 2 diabetes Key takeaways: Adults with type 2 diabetes using tirzepatide had a 20% lower risk for major adverse CV events than those using dulaglutide
However, it is important to consider that patterns of body weight and adipose tissue distribution vary significantly across different racial groups [22]
And then the question becomes simply, as David has been suggesting, are they doing much the same thing
Oxidative stress in atherogenesis and arterial thrombosis: the disconnect between cellular studies and clinical outcomes
Regions that lack a well-defined three-dimensional structure represent a major functional advantage, as they enable proteins to interact with a broad range of substrates with relatively high specificity and low-affinity
Beeraka NM, Bovilla VR, Doreswamy SH, Puttalingaiah S, Srinivasan A, Madhunapantula SV